SCHEMBL4139330

SCHEMBL4139330

N#Cc1ccccc1-c1ccc(/C=C2\SC(Nc3ccc(CC(=O)O)cc3)=NC2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 7/20 0.39
MME P08473 1/20 0.39
FFAR1 O14842 2/20 0.39
AKR1B1 P15121 1/20 0.39
AGTR1 P30556 1/20 0.38
DUSP3 P51452 1/20 0.37
DUSP22 Q9NRW4 1/20 0.37
DGAT1 O75907 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
PDE4B Q07343 2/20 0.35
MYC P01106 1/20 0.35
WDR5 P61964 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139334 1.00 ALOX5 (0.39) ALOX5MMEFFAR1AKR1B1AGTR1
SCHEMBL4132443 0.86 FFAR1 (0.47) ALOX5FFAR1AKR1B1DUSP3DUSP22
SCHEMBL4132445 0.86 FFAR1 (0.47) ALOX5FFAR1AKR1B1DUSP3DUSP22
SCHEMBL4133991 0.86 PDE4B (0.44) ALOX5FFAR1DUSP3DUSP22PDE4B
SCHEMBL4133988 0.86 PDE4B (0.44) ALOX5FFAR1DUSP3DUSP22PDE4B
SCHEMBL4133862 0.84 DUSP22 (0.49) ALOX5FFAR1AKR1B1DUSP3DUSP22
SCHEMBL4133860 0.84 DUSP22 (0.49) ALOX5FFAR1AKR1B1DUSP3DUSP22
SCHEMBL4120209 0.83 AGTR1 (0.38) ALOX5FFAR1AKR1B1AGTR1S1PR1
SCHEMBL4120214 0.83 AGTR1 (0.38) ALOX5FFAR1AKR1B1AGTR1S1PR1
SCHEMBL4122531 0.81 ALOX5 (0.46) ALOX5FFAR1AKR1B1DUSP3DUSP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885MME 4527/4885FFAR1 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.